At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More
Net Sales are expected to increase by 11.2 percent Y-o-Y (up 3 percent Q-o-Q) to Rs. 431.1 crore, according to ICICI Direct.
Net Sales are expected to increase by 24.8 percent Y-o-Y (up 3 percent Q-o-Q) to Rs. 418.2 crore, according to ICICI Direct.
EBITDA Margins around 31-33% with focus on growth and investments are good, said Jonathan Hunt, CEO of Syngene International.
From a revenue point of view, they have now surpassed the level they were at pre-fire. However, on the operational side the building is still out of action, said Jonathan Hunt, CEO of Syngene.
Of USD 200 million capex, USD 100 million will go into four key areas- Syngene Research Centre, biologic centre, formulation center, viral testing and the rest in commercial manufacturing, says Jonathan Hunt, CEO of Syngene International.
Factors to watch out for in Q1 would be margin, contract research business, R&D cost, pricing pressure in legacy API biz (especially statins), recovery in branded formulation (was flat in Q4 due to restructuring) and pick up in Middle East market (did well in Q4).
Manoj Nerurkar, COO, Syngene, says he expects the company to grow in line with its second quarter results.
Peter Bains, Director & CEO of Syngene told CNBC-TV18 growing client base and expanding capacity will aid growth in future.